QID 317305

Date Published: 2023-04-03

QID 317305: Cisco Internetwork Operating System (IOS) and IOS XE Software Internet Protocol (IPv6) DHCP (DHCPv6) Relay and Server Denial of Service (DoS) Vulnerability (cisco-sa-ios-dhcpv6-dos-44cMvdDK)

A vulnerability in the IPv6 DHCP version 6 (DHCPv6) relay and server features of Cisco IOS and IOS XE Software could allow an unauthenticated, remote attacker to trigger a denial of service (DoS) condition.

Affected Products
This vulnerability affects Cisco devices if they are running a vulnerable release of Cisco IOS or IOS XE Software and have IPv6 and the DHCPv6 relay or server feature enabled. IPv6 and DHCPv6 are disabled in Cisco IOS and IOS XE Software by default.
QID Detection Logic (Authenticated): The check matches Cisco IOS XE version retrieved via Unix Auth using "show version" command. QID Detection Logic (Unauthenticated): The check matches Cisco IOS XE version retrieved via SNMP or TCP/IP Fingerprint or NTP or Telnet.

A successful exploit could allow the attacker to cause the device to reload unexpectedly.

  • CVSS V3 rated as High - 7.5 severity.
  • CVSS V2 rated as High - 7.8 severity.
    • Solution

    Customers are advised to refer to cisco-sa-ios-dhcpv6-dos-44cMvdDK for more information.

    Vendor References

    CVEs related to QID 317305

    CVE-2023-20080 |
    Software Advisories
    Advisory ID Software Component Link
    cisco-sa-ios-dhcpv6-dos-44cMvdDK URL Logo sec.cloudapps.cisco.com/security/center/content/CiscoSecurityAdvisory/cisco-sa-ios-dhcpv6-dos-44cMvdDK
    By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].